Preliminary report suggests combination therapy may help treat SARS

December 23, 2003

CHICAGO - A preliminary study suggests that use of a combination of corticosteroids and interferon may have a role in treatment of severe acute respiratory syndrome (SARS), according to an article in the December 24/31 issue of The Journal of the American Medical Association (JAMA).

According to background information in the article, SARS is characterized by fever, lower respiratory tract symptoms, and abnormal findings on chest x-ray. As of September 26, 2003, the World Health Organization has recorded 8,098 SARS cases and 774 SARS-related deaths from 27 countries. Treatment for SARS has included antibiotic therapy, corticosteroids and other drug therapies, but there is little compelling evidence that these strategies improve outcome. A group of drugs called interferons inhibit viral infections by boosting the body's immune response. In laboratory experiments, interferons were effective in inhibiting a strain of a SARS-related virus.

Mona R. Loutfy, M.D., M.P.H., of the North York General Hospital, Toronto, Ontario, and colleagues conducted a study between April 11 and May 30, 2003, to assess the use of corticosteroids vs. corticosteroids plus subcutaneous interferon alfacon-1 in 22 patients diagnosed as having probable SARS.

Thirteen patients were treated with corticosteroids alone and nine patients were treated with corticosteroids plus interferon alfacon-1. The patients included 16 women and 6 men ranging in age from 16 to 86 years.

The researchers found that the resolution of fever was similar between the two treatment groups. Of the 13 patients treated with corticosteroids alone, 5 (38.5 percent) were transferred to the intensive care unit, 3 (23.1 percent) required intubation and mechanical ventilation, and 1 (7.7 percent) died. Of the nine patients in the interferon alfacon-1 treatment group, 3 (33.3 percent) were transferred to the intensive care unit, 1 (11.1 percent) required intubation and mechanical ventilation, and none died.

The researchers also found that the interferon alfacon-1 group experienced a shorter time to resolution of chest x-ray abnormalities, and required supplemental oxygen for a shorter period of time.

"These preliminary findings suggest that treatment with interferon alfacon-1 and steroids was associated with more rapid resolution of radiographic lung abnormalities and better oxygen saturation levels than treatment with corticosteroids alone," write the authors.

"These findings suggest that further investigation may be warranted to determine the role of interferon alfacon-1 as a therapeutic agent for the treatment of SARS," conclude the researchers.
-end-
(JAMA. 2003;290:3222-3228. Available post-embargo at jama.com)

Editor's Note: This work was funded by a grant from the Canadian Institutes of Health Research (CIHR) and Ontario Research and Development Challenge Fund (ORDCF) to Drs. Siminovitch, Dennis and Fish. Intermune Corp. provided the interferon alfacon-1 at no cost. Dr. Kain holds a Canada Research Chair, Dr. Loutfy is a CIHR postdoctoral fellow (McGill University, Montreal, Quebec), and Dr. Siminovitch is a CIHR senior scientist.

For More Information: Contact the JAMA/Archives Media Relations Department at 312/464-JAMA (5262) or e-mail: jamaarchmedia@ama-assn.org.

The JAMA Network Journals

Related Corticosteroids Articles from Brightsurf:

Corticosteroids improve survival in critically ill COVID-19 patients
In a tremendous demonstration of global collaboration, clinician-scientists have pooled data from 121 hospitals in eight countries to find that inexpensive, widely available steroids improve the odds that very sick COVID-19 patients will survive the illness.

Association between treatment with corticosteroids, risk of death among critically ill patients with COVID-19
The results of seven randomized clinical trials with 1,703 critically ill patients with COVID-19 were combined to estimate the association between administration of corticosteroids compared with usual care or placebo and the risk of death after 28 days.

A dual antenatal therapy benefits extreme preterm babies better than either alone or none
Researchers, led by Samuel Gentle, MD, assistant professor of pediatrics in the University of Alabama at Birmingham School of Medicine, report that antenatal treatment with both magnesium sulfate and corticosteroids together yields an increased benefit for children born at 22 to 26 weeks of gestation, compared to no antenatal treatment or with either therapy alone.

Behavioral disorders more common in children exposed to maternal antenatal corticosteroids
Maternal antenatal corticosteroid treatment is standard care when there is a risk for preterm delivery.

New method identifies which asthma patients respond to systemic corticosteroids
Physicians will be able to predict which of their patients with severe asthma are likely to benefit from treatment with systemic corticosteroids -- and which might only suffer their side effects -- with help from a dozen clinical variables researchers have identified using machine learning techniques, say researchers at Carnegie Mellon University and the University of Pittsburgh School of Medicine.

Study reveals a promising alternative to corticosteroids in acute renal failure treatment
In search of an option for the drug known for causing several side effects, scientists describe the anti-inflammatory properties of protein galectin-1 in tests with rats involving ischemia-reperfusion scenarios.

Long-term usage of inhaled corticosteroids may increase risk of bone fractures in patients with COPD
A study published in the February journal CHEST® suggests long-term inhaled corticosteroids (ICS) in patients with COPD may increase risk of bone fractures in both men and women.

Corticosteroids aid healing -- if the timing is right
A corticosteroid can improve the healing of damaged tendons, but it must be given at the right time, according to a new study from Linköping University in Sweden.

Interventions for treating tuberculous pericarditis
Researchers from South Africa and Canada have carried out a Cochrane review update to assess the safety and effectiveness of corticosteroids for treating tuberculous pericarditis.

New medicine shows potential to reduce oral steroid use in severe asthma patients
The results of the trial, published this week in the New England Journal of Medicine, demonstrate that patients treated with a potential new medicine and antibody, called benralizumab, were more than four times likely to reduce their usage of oral corticosteroids than those taking a placebo.

Read More: Corticosteroids News and Corticosteroids Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.